Discovery of Pyrrolopyrazine Carboxamide Derivatives as Potent and Selective FGFR2/3 Inhibitors that Overcome Mutant Resistance
Journal of Medicinal Chemistry · 2025
DOI: 10.1021/acs.jmedchem.4c03205 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, 2025. Verfasst von Yazhou Wang und 16 weiteren Autor:innen. Beteiligte Einrichtung: Insilico Medicine Shanghai Ltd, Suite 901, Tower C, Changtai Plaza, 2889 Jinke Road, Pudong New District, Shanghai 201203, China. Hauptthemen laut MEDLINE: Receptor, Fibroblast Growth Factor, Type 2, Receptor, Fibroblast Growth Factor, Type 3, Protein Kinase Inhibitors. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 42 Literaturangaben.
Abstract (Originalsprache)
Fibroblast growth factor receptors (FGFRs) are established oncogenic drivers in various solid tumors. However, the approved FGFR inhibitors face challenges with acquired resistance and dose-limiting adverse effects associated with FGFR1/4 inhibition, limiting therapeutic efficacy. Herein, we systematically explored linker and electrophile moieties based on the pyrrolopyrazine carboxamide core and identified aniline α-fluoroacrylamide as an effective covalent warhead. Compound 10 potently inhibited FGFR2 and FGFR3, even in the context of common inhibitor-resistance mutations, including in the gatekeeper, molecular brake, and activation loop regions. Compound 10 spared FGFR1/4 and other kinases without causing diarrhea and serum phosphate elevation in vivo . Oral administration of compound 10 induced tumor stasis or regression in the SNU-16 gastric cancer model with favorable pharmacokinetics and robust pharmacodynamic suppression.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Insilico Medicine Shanghai Ltd, Suite 901, Tower C, Changtai Plaza, 2889 Jinke Road, Pudong New District, Shanghai 201203, China.
- GenFleet Therapeutics (Shanghai) Inc., Shanghai 201203, China.
- Insilico Medicine AI Limited, Masdar City, Abu Dhabi 145748, UAE.
ORCID-Profile: Alex Aliper, Feng Ren, Alex Zhavoronkov, Xiao Ding
Zitieren
APA
Wang, Y., Zhang, Y., Liu, J., Zhao, J., Wang, C., Meng, F., Cai, X., Zhang, M., Aliper, A., Liang, T., Yan, F., Ren, F., Lan, J., Lu, Q., Zhou, F., Zhavoronkov, A., & Ding, X. (2025). Discovery of Pyrrolopyrazine Carboxamide Derivatives as Potent and Selective FGFR2/3 Inhibitors that Overcome Mutant Resistance. Journal of Medicinal Chemistry. https://doi.org/10.1021/acs.jmedchem.4c03205
Vancouver
Wang Y, Zhang Y, Liu J, Zhao J, Wang C, Meng F, et al. Discovery of Pyrrolopyrazine Carboxamide Derivatives as Potent and Selective FGFR2/3 Inhibitors that Overcome Mutant Resistance. Journal of Medicinal Chemistry. 2025. doi:10.1021/acs.jmedchem.4c03205
BibTeX
@article{Wang2025,
author = {Wang, Yazhou and Zhang, Yihong and Liu, Jinxin and Zhao, Jichen and Wang, Chao and Meng, Fanye and Cai, Xin and Zhang, Man and Aliper, Alex and Liang, Tao and Yan, Feng and Ren, Feng and Lan, Jiong and Lu, Qiang and Zhou, Fusheng and Zhavoronkov, Alex and Ding, Xiao},
title = {Discovery of Pyrrolopyrazine Carboxamide Derivatives as Potent and Selective FGFR2/3 Inhibitors that Overcome Mutant Resistance},
journal = {Journal of Medicinal Chemistry},
year = {2025},
doi = {10.1021/acs.jmedchem.4c03205}
}
EUVIMED